We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shire Cancer Drug Onivyde Receives EU Marketing Approval
Read MoreHide Full Article
Shire plc announced that the European Commission has granted marketing authorization to Onivyde, in combination with fluorouracil (5-FU) and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following treatment with Eli Lilly and Company’s (LLY - Free Report) Gemzar-based therapy.
The approval did not come as a surprise given that Onivyde had been granted a positive opinion from the Committee for Medicinal Products for Human Use in July.
With the approval, Shire is authorized to market Onivyde, also known as nal-IRI or MM-398, in the EU, Iceland, Liechtenstein and Norway. Note that Onivyde is already approved in the U.S. for this indication.
The marketing approval was based on positive data from the NAPOLI-1 study.
The study met the primary and secondary endpoints as Onivyde, in combination with 5-Fu/Lv, significantly improved overall survival, progression-free survival and objective response compared to 5-FU/LV alone in patients with metastatic pancreatic cancer.
However there were some adverse reactions (incidence ≥20 percent) associated with treatment of Onivde in combination with 5-Fu/Lv. These included diarrhea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anemia, stomatitis, and pyrexia.
We note that Shire has a licensing agreement with Merrimack Pharmaceuticals, Inc. (MACK - Free Report) , under which the former is responsible for the development and commercialization of Onivyde outside the U.S. and Taiwan. In Taiwan, PharmaEngine holds the commercialization rights to Onivyde, after the product license was granted in Mar 2016. Meanwhile in the U.S., Merrimack markets the drug.
According to the company’s press release, pancreatic cancer is the fourth leading cause of cancer-related death and there are limited treatment options available. Therefore, the approval of Onivyde is in line with Shire's focus of developing and commercializing treatments for the most promising markets of oncology.
Exelixis’s loss estimates narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 3 cents for 2017 over the last 60 days. The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has skyrocketed over 100% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Shire Cancer Drug Onivyde Receives EU Marketing Approval
Shire plc announced that the European Commission has granted marketing authorization to Onivyde, in combination with fluorouracil (5-FU) and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following treatment with Eli Lilly and Company’s (LLY - Free Report) Gemzar-based therapy.
The approval did not come as a surprise given that Onivyde had been granted a positive opinion from the Committee for Medicinal Products for Human Use in July.
With the approval, Shire is authorized to market Onivyde, also known as nal-IRI or MM-398, in the EU, Iceland, Liechtenstein and Norway. Note that Onivyde is already approved in the U.S. for this indication.
The marketing approval was based on positive data from the NAPOLI-1 study.
The study met the primary and secondary endpoints as Onivyde, in combination with 5-Fu/Lv, significantly improved overall survival, progression-free survival and objective response compared to 5-FU/LV alone in patients with metastatic pancreatic cancer.
However there were some adverse reactions (incidence ≥20 percent) associated with treatment of Onivde in combination with 5-Fu/Lv. These included diarrhea, nausea, vomiting, decreased appetite, neutropenia, fatigue, asthenia, anemia, stomatitis, and pyrexia.
We note that Shire has a licensing agreement with Merrimack Pharmaceuticals, Inc. (MACK - Free Report) , under which the former is responsible for the development and commercialization of Onivyde outside the U.S. and Taiwan. In Taiwan, PharmaEngine holds the commercialization rights to Onivyde, after the product license was granted in Mar 2016. Meanwhile in the U.S., Merrimack markets the drug.
According to the company’s press release, pancreatic cancer is the fourth leading cause of cancer-related death and there are limited treatment options available. Therefore, the approval of Onivyde is in line with Shire's focus of developing and commercializing treatments for the most promising markets of oncology.
SHIRE PLC-ADR Price
SHIRE PLC-ADR Price | SHIRE PLC-ADR Quote
Zacks Rank & a Stock to Consider
Shire carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Exelixis, Inc (EXEL - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis’s loss estimates narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 3 cents for 2017 over the last 60 days. The company has posted a positive surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has skyrocketed over 100% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>